ABUS peer analysis
Arbutus Biopharma (ABUS) against its competitors: price, today's move, 1-year return and market value side by side.
ABUS and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALGS Aligos Therapeutics | $4.60 | -4.17% | -46.57% | – |
| ALNY Alnylam | $158.00 | -4.24% | -65.35% | $22.10B |
| ARWR Arrowhead | $59.57 | -0.55% | 40.53% | $8.46B |
| ASMB Assembly Biosciences | $19.51 | -3.08% | -37.17% | $409.86M |
| AVIR Atea Pharmaceuticals | $4.10 | -0.24% | 26.15% | – |
| BNTC Benitec Biopharma | $8.49 | -2.86% | -48.11% | $304.93M |
| ENTA Enanta Pharmaceuticals | $10.43 | -2.61% | -4.84% | $311.93M |
| SLN Silence Therapeutics | $19.76 | 0.05% | 175.98% | – |
| VIR Vir Biotechnology | $11.00 | -2.65% | 84.56% | $1.91B |
| ABUS Arbutus Biopharma | $4.00 | -4.99% | -15.43% | $834.03M |
- ABUS's peers: ALGS (Aligos Therapeutics), ALNY (Alnylam), ARWR (Arrowhead), ASMB (Assembly Biosciences), AVIR (Atea Pharmaceuticals), BNTC (Benitec Biopharma), ENTA (Enanta Pharmaceuticals), SLN (Silence Therapeutics).
Updated 2026-11-03 11:32 UTC